Obinutuzumab Versus Rituximab for Acute Lymphoblastic Leukemia/PALG ALL7 "OVERALL" (clinicaltrials.gov) - Oct 15, 2026 - P2 | N=49 | Terminated | Sponsor: Maria Sklodowska-Curie National Research Institute of Oncology | N=124 ➔ 49 | Trial completion date: Dec 2025 ➔ Apr 2026 | Recruiting ➔ Terminated | Trial primary completion date: Dec 2025 ➔ Apr 2026; Following the recommendation of the Data Monitoring Committee (DMC), based on the results of the interim analysis, the Sponsor has decided to terminate the study prematurely
Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology • CD20
|